Companies › Apogee Therapeutics
2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Immunology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APG777 IL-4 receptor antagonist | IL4R | Phase 2 | Atopic Dermatitis; Asthma | Nov 2026 |
| APG990 | – | Phase 1 | Atopic Dermatitis | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06395948 | APG777 | Phase 2 | Atopic Dermatitis | Immunology | Nov 2026 |
| NCT06920901 | APG777 | Phase 1 | Asthma | Respiratory | Mar 2027 |
| NCT07027527 | APG777 | Phase 1 | Atopic Dermatitis | Immunology | Dec 2027 |
| NCT07027527 | APG990 | Phase 1 | Atopic Dermatitis | Immunology | Dec 2027 |
| NCT07003425 | APG777 | Phase 2 | Atopic Dermatitis | Immunology | Dec 2029 |
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Guangdong Hengrui Pharmaceutical Sanofi Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Uniquity One (UNI) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical
Jiangsu Genscend Biopharmaceutical Guangdong Hengrui Pharmaceutical Genrix (Shanghai) Biopharmaceutical Prana Therapies Enveda Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.